Open Access
Open access
Signal Transduction and Targeted Therapy, volume 8, issue 1, publication number 115

AlphaFold2 and its applications in the fields of biology and medicine

Publication typeJournal Article
Publication date2023-03-14
Quartile SCImago
Q1
Quartile WOS
Q1
Impact factor39.3
ISSN20959907, 20593635
Cancer Research
Genetics
Abstract

AlphaFold2 (AF2) is an artificial intelligence (AI) system developed by DeepMind that can predict three-dimensional (3D) structures of proteins from amino acid sequences with atomic-level accuracy. Protein structure prediction is one of the most challenging problems in computational biology and chemistry, and has puzzled scientists for 50 years. The advent of AF2 presents an unprecedented progress in protein structure prediction and has attracted much attention. Subsequent release of structures of more than 200 million proteins predicted by AF2 further aroused great enthusiasm in the science community, especially in the fields of biology and medicine. AF2 is thought to have a significant impact on structural biology and research areas that need protein structure information, such as drug discovery, protein design, prediction of protein function, et al. Though the time is not long since AF2 was developed, there are already quite a few application studies of AF2 in the fields of biology and medicine, with many of them having preliminarily proved the potential of AF2. To better understand AF2 and promote its applications, we will in this article summarize the principle and system architecture of AF2 as well as the recipe of its success, and particularly focus on reviewing its applications in the fields of biology and medicine. Limitations of current AF2 prediction will also be discussed.

Top-30

Journals

1
2
3
4
5
International Journal of Biological Macromolecules
5 publications, 3.45%
International Journal of Molecular Sciences
4 publications, 2.76%
Journal of Chemical Information and Modeling
3 publications, 2.07%
Briefings in Bioinformatics
3 publications, 2.07%
Computational and Structural Biotechnology Journal
3 publications, 2.07%
Nature Communications
3 publications, 2.07%
Molecules
2 publications, 1.38%
ACS Omega
2 publications, 1.38%
Journal of Physical Chemistry B
2 publications, 1.38%
Molecular Diversity
2 publications, 1.38%
Biomolecules
2 publications, 1.38%
Computers in Biology and Medicine
2 publications, 1.38%
Current Opinion in Structural Biology
2 publications, 1.38%
Biophysical Journal
2 publications, 1.38%
Frontiers in Immunology
2 publications, 1.38%
Protein Science
2 publications, 1.38%
Plant Physiology and Biochemistry
2 publications, 1.38%
Frontiers in Genetics
2 publications, 1.38%
Expert Opinion on Drug Discovery
1 publication, 0.69%
Acta Biomaterialia
1 publication, 0.69%
Journal of Translational Medicine
1 publication, 0.69%
Frontiers in Physiology
1 publication, 0.69%
Journal of Molecular Biology
1 publication, 0.69%
Antibiotics
1 publication, 0.69%
Biophysical Reviews
1 publication, 0.69%
Molecular Physics
1 publication, 0.69%
Frontiers in Lab on a Chip Technologies
1 publication, 0.69%
Molecular Aspects of Medicine
1 publication, 0.69%
Pharmacology and Therapeutics
1 publication, 0.69%
1
2
3
4
5

Publishers

5
10
15
20
25
30
35
40
45
Elsevier
45 publications, 31.03%
Springer Nature
19 publications, 13.1%
MDPI
15 publications, 10.34%
Cold Spring Harbor Laboratory
14 publications, 9.66%
Frontiers Media S.A.
11 publications, 7.59%
American Chemical Society (ACS)
10 publications, 6.9%
Wiley
10 publications, 6.9%
Oxford University Press
4 publications, 2.76%
Taylor & Francis
3 publications, 2.07%
Research Square Platform LLC
3 publications, 2.07%
American Society for Microbiology
2 publications, 1.38%
Royal Society of Chemistry (RSC)
1 publication, 0.69%
World Scientific
1 publication, 0.69%
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 0.69%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.69%
Biophysical Society of Japan
1 publication, 0.69%
Public Library of Science (PLoS)
1 publication, 0.69%
IGI Global
1 publication, 0.69%
American Society of Clinical Oncology (ASCO)
1 publication, 0.69%
5
10
15
20
25
30
35
40
45
  • We do not take into account publications without a DOI.
  • Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Share
Cite this
GOST |
Cite this
GOST Copy
YANG Z. et al. AlphaFold2 and its applications in the fields of biology and medicine // Signal Transduction and Targeted Therapy. 2023. Vol. 8. No. 1. 115
GOST all authors (up to 50) Copy
YANG Z., Zeng X., Zhao Y., CHEN R. AlphaFold2 and its applications in the fields of biology and medicine // Signal Transduction and Targeted Therapy. 2023. Vol. 8. No. 1. 115
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/s41392-023-01381-z
UR - https://doi.org/10.1038/s41392-023-01381-z
TI - AlphaFold2 and its applications in the fields of biology and medicine
T2 - Signal Transduction and Targeted Therapy
AU - YANG, ZHENYU
AU - Zeng, Xiaoxi
AU - Zhao, Yi
AU - CHEN, RUNSHENG
PY - 2023
DA - 2023/03/14
PB - Springer Nature
IS - 1
VL - 8
SN - 2095-9907
SN - 2059-3635
ER -
BibTex
Cite this
BibTex Copy
@article{2023_YANG,
author = {ZHENYU YANG and Xiaoxi Zeng and Yi Zhao and RUNSHENG CHEN},
title = {AlphaFold2 and its applications in the fields of biology and medicine},
journal = {Signal Transduction and Targeted Therapy},
year = {2023},
volume = {8},
publisher = {Springer Nature},
month = {mar},
url = {https://doi.org/10.1038/s41392-023-01381-z},
number = {1},
doi = {10.1038/s41392-023-01381-z}
}
Found error?